Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Pemigatinib, Azacitidine, TAK-611 Get Orphan Tag in Japan
June 22, 2022
- Health Minister Defends Govt Purchase Pact for Shionogi’s COVID Pill
June 21, 2022
- Japan Approves Janssen’s COVID Jab, Sanofi’s Sutimlimab, Olumiant’s Alopecia Use and More
June 21, 2022
- MHLW Wants to Boost Preparedness with Proposed Pandemic Response Division: Minister
June 20, 2022
- PMDA Clears All Its Review Targets, Processed Relief Claims at Record Speed in FY2021
June 20, 2022
- Govt Officially OKs Launch of Pandemic Response Agency, Japan CDC
June 20, 2022
- Japan Detects 11 More Probable Cases of Mysterious Hepatitis in Children
June 20, 2022
- As Election Campaigns Begin, Parties Pitch Policies to Bolster Drug Development, Supply Chains
June 17, 2022
- New NIBIOHN Chief Eager to Bridge Void to Develop Innovative Drug Discovery Platform
June 17, 2022
- First Two Vaccine Projects Adopted for SCARDA Funding
June 17, 2022
- Feburic, Samsca, and More Face First Generics in June Listing, No Xarelto/Eylea AGs
June 16, 2022
- Kishida Officially Unveils Plan to Form Pandemic Response Agency, Japan CDC
June 16, 2022
- Shionogi’s COVID Pill Up for PAFSC Review for 1st Emergency Approval
June 16, 2022
- MHLW Proposes KPIs for Creation of Drug Discovery Ecosystem, 3 Other Areas
June 15, 2022
- Japan to Create Expert Panel to Ponder Drug Distribution and Pricing: Kanmin Taiwa
June 15, 2022
- Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
June 15, 2022
- MSD and Pfizer COVID Pills Add Anaphylaxis in ADR List: Label Update
June 15, 2022
- MHLW Publishes Guidelines for Evaluating SaMDs Used for Behavioral Modification
June 15, 2022
- Lawmakers’ Group Pushes for Legal Steps to Eliminate Drug Lag for Children
June 14, 2022
- LDP’s COVID HQ Compiles Mid-to-Long Term Proposal for Future Pandemics
June 14, 2022
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…